IKBKE and obesity due to melanocortin 4 receptor deficiency: Amlexanox is an anti-inflammatory, anti-allergic, immunomodulator and has been developed for the treatment of ulcers, allergic rhinitis and asthma in the clinic.12 Recently, amlexanox was found to be an inhibitor of the protein kinases TBK1/IKBKE and improve obesity related metabolic dysfunction.13 In the present study, we identified amlexanox as a potent anti-glioma drug by downregulating IKBKE.